Abstract Library

#3670 Response to peptide receptor radionuclide therapy in pheochromocytomas and paragangliomas – A systematic review and meta-analysis

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC has shown efficacy in the metastatic setting of pheochromocytomas (PCCs) and paragangliomas (PGLs) where no standard therapies have been established.

Conference:

Presenting Author: Marretta A

Authors: Marretta A, Ottaiano A, Iervolino D, Bracigliano A, Clemente O,

Keywords: PRRT, Pheochromocytoma, Paraganglioma, Neuroendocrine Tumor, Meta-analysis,

#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Prasad V, Erdmann S, Wiedenmann B,

Keywords: PRRT,

#1817 Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer

Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Dureja S

Authors: Dureja S, Thakral P, Pant V, Pallavi U, Vindhya M,

Keywords: PRRT, radiosensitizer,

#1506 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: PRRT can deliver radiation doses of up to 250 Gy to the tumors. Nevertheless, complete remission is extremely rare, compared to similar radiotherapies for thyroid cancer and non-Hodgkin lymphoma.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Exner S, Erdmann S, Wiedenmann B, Prasad V, Grötzinger C,

Keywords: PRRT,

#613 Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models

Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Cullinane C

Authors: Cullinane C, Waldeck K, Kirby L, Eu P, Hicks R,

Keywords: preclinical models, PRRT, radiosensitizer,